Review ArticleAtypical antipsychotics in the treatment of psychotic symptoms in Alzheimer’s disease: a systematic reviewVinaşi, Ramonaa; Buciuta, Andreib; Coman, Horia GeorgecAuthor Information aDepartment of Psychiatry bDepartment of Cellular and Molecular Biology cDepartment of Medical Psychology, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania Received 13 November 2020 Accepted 5 March 2021 Correspondence to Horia Coman, MD, PhD, Department of Medical Psychology, Iuliu Hatieganu University of Medicine and Pharmacy Cluj-Napoca, 43rd V. Babeş Street, 400012 Cluj-Napoca, Romania, Tel: +40 745 646043; fax: +40 264 590576; e-mail: [email protected] International Clinical Psychopharmacology: July 2021 - Volume 36 - Issue 4 - p 169-180 doi: 10.1097/YIC.0000000000000358 Buy Metrics Abstract With the advancement of Alzheimer’s disease as well as other types of dementia, in addition to the cognitive decline, psychiatric symptoms have been outlined, including psychotic symptoms. The aim of the study is to review the available results on the antipsychotic treatment of Alzheimer’s disease associated psychotic symptoms. The main objective of the study is to evaluate the efficacy of the treatment. The second objective is to assess the tolerability of this treatment. Double-blind, randomized, placebo-controlled trials, which took place over the course of at least 4 weeks, have been searched. Studies that compared one atypical antipsychotic to placebo, as well as more atypical antipsychotics, compared one to another, have been taken into account. In total 17 studies have been selected. The efficacy of the atypical antipsychotics has proven to be significant in most studies. Moreover, antipsychotic medication, such as risperidone, aripiprazole, olanzapine, quetiapine and pimavanserin, has been well tolerated. Atypical antipsychotics are the treatment of choice for psychotic symptoms in dementia. Despite the consistent results present in the literature up to this point, various antipsychotics remain insufficiently studied and would need more generous sample sizes for their outcomes to be substantiated. Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.